[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"John Elfar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,78,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100561920","phase-2-4-aminopyridine-to-treat-skin-burns-100561920",false,"NCT06596434","4-Aminopyridine to Treat Skin Burns","Inclusion Criteria:\n\n* Injured (burned) adults with a maximum severity of second-degree burns.\n* Burns involving at least 6cm2 of skin area\n* Acute burns within 7 days of injury\n* Cognitive ability to evaluate burn healing, report sensory and motor deficit during examination.\n* Adults aged 18-80\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.",[25,26,27],"Burns","Second Degree Burn","Wounds and Injuries",[29,30,25,31,32],"4-aminopyridine","4-AP","Second degree burn","Wounds","RECRUITING","2026-03-04",{"date":36,"type":37},"2026-03-05","ACTUAL",{"date":39,"type":37},"2026-01-01",{"date":41,"type":19},"2028-09",{"name":43,"class":44},"John Elfar","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100538744","phase-2-4ap-for-carpal-tunnel-syndrome-cts-100538744","NCT06294821","4AP for Carpal Tunnel Syndrome (CTS)","4-Aminopyridine to Delay Carpal Tunnel Release or Resolve Carpal Tunnel Syndrome","CTS","Inclusion Criteria:\n\n* Patients diagnosed with non-traumatic carpal tunnel syndrome without any other confounding diagnosis (e.g. cubital tunnel syndrome, cervical nerve compression)\n* Standard of care EDX testing within 6 months of study enrollment\n* Cognitive ability to report sensory and motor deficit during examination.\n* Able to complete twice daily dosing of 4-AP for the entire 6 week treatment period.\n* Adults subject aged 18-90\n* Ability to give written informed consent.\n* Capable of safely undergoing electrodiagnostic testing (EDX).\n* Availability for all study visits.\n\nExclusion Criteria:\n\n* Inability to complete twice daily dosing during 6 week treatment period.\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.","90 Years",{"count":56,"type":19},160,[22],"The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can treat carpal tunnel syndrome or delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.",[60,61],"Compression Neuropathy","Carpal Tunnel Syndrome",[63,64,65,66,52,67,68],"4 aminopyridine","carpal tunnel syndrome","CTR","4AP","Carpal tunnel release","compression neuropathy","NOT_YET_RECRUITING","2026-01-22",{"date":72,"type":37},"2026-01-26",{"date":74,"type":19},"2026-11",{"date":76,"type":19},"2028-07",{"name":43,"class":44},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":20,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100339597","phase-2-4-aminopyridine-treatment-for-nerve-injury-100339597","NCT03701581","4-aminopyridine Treatment for Nerve Injury","4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy","Inclusion Criteria\n\n* Male patients with organ-confined, non-metastatic prostate cancer (stages cT1c-T2c), planning to undergo Robotic-Assisted Laparoscopic Bilateral Nerve Sparing Radical Prostatectomy (NSRP)\n* Prostate-Specific Antigen (PSA) levels less than 15 ng\u002Fml (within the last 12 months), with biopsy-proven prostate cancer, for whom postoperative adjuvant therapy (e.g. radiation or androgen deprivation therapy) is not expected to be needed\n* Ages 45-75\n* An Abridged International Index of Erectile Function-Erectile Function (IIEF-5) score of greater than or equal to 17 at time of screening\n* Has experienced at least 6 months of regular sexual activity and sexual activity during the 12 weeks prior to prostate biopsy or surgery\n* Willingness to abstain from treatments for Erectile Dysfunction until 3 months after surgery\n* Willingness to participate and able to provide informed consent\n\nExclusion Criteria\n\n* Planned adjuvant therapy after NSRP based on specimen pathology and stage of prostate cancer (stage T3 or greater), positive lymph nodes or positive surgical margins\n* Neo-adjuvant therapy prior to NSRP\n* History of recurrent prostate cancer\n* History of seizures, multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of non-organ confined or metastatic prostate cancer (clinical Stages T3 or greater)\n* History of known hypersensitivity to 4AP\n* Patients with history of penile surgery other than circumcision or endoscopic urethral stricture surgery\n* Renal impairment based on calculated GFR (GFR\\\u003C60 mL\u002Fmin)\n* Use of any other aminopyridine medications for any other indication","MALE","45 Years","75 Years",{"count":89,"type":19},70,[22,91],"PHASE3","To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and\u002For crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and\u002For crush injuries.",[94,95],"Nerve Injury","Prostate Cancer",[97,98,99,100,101],"prostatectomy","erectile dysfunction","prostate cancer","nerve injury","incontinence","2025-12-15",{"date":104,"type":37},"2025-12-17",{"date":106,"type":37},"2021-06-05",{"date":108,"type":19},"2028-12",{"name":43,"class":44},2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":15,"minAge":16,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":20,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100541692","phase-2-4-aminopyridine-for-skin-wound-healing-100541692","NCT06333171","4-aminopyridine for Skin Wound Healing","Inclusion Criteria:\n\n* Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.\n* Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.\n* Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).\n* Adults subject aged 18-70\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds",true,"70 Years",{"count":120,"type":19},150,[22],"Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.\n\nThe purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.\n\nThe investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.",[32,124,125,27],"Wound of Skin","Wound Heal",[63,127],"wound healing","2025-09-01",{"date":130,"type":37},"2025-09-03",{"date":132,"type":19},"2025-09",{"date":134,"type":19},"2028-03",{"name":43,"class":44},""]